Goel, Shom; Chirgwin, Jacquie; Francis, Prudence; Stuart-Harris, Robin; Dewar, Joanna; Mileshkin, Linda; Snyder, Raymond; Michael, Michael; Koczwara, Bogda
The management of HER2-positive metastatic breast cancer, a disease renowned for its aggressive natural history, has been revolutionized by the introduction of trastuzumab. Indeed, outcomes for patients with HER2-positive advanced breast cancer are now equivalent to, if not better than, those of their HER2-negative counterparts. Since the pivotal registration trial, a wealth of new clinical data has emerged regarding the use of trastuzumab in a variety of clinical contexts - adding to the...[Show more]
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.